Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

Cannabis appears to have no effect on breathlessness during exercise in advanced COPD patients

Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Rheumatoid Arthritis: A systematic approach (edited by Dr. Syuichi Koarada) comprehensively covers each aspect of the pathology, diagnosis and treatment of rheumatoid arthritis.

26 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.

30 May 2018

Researchers find new method to treat severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.

23 May 2018

Eczema drug alleviates asthma symptoms and improves lung function

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe better than standard therapies.

22 May 2018

Guideline revisions for knee osteoarthritis have 'subtle but significant' impact on clinical practice

Recent updates in evidence-based recommendations have led to changes in the use of steroid and hyaluronic acid injection for patients with osteoarthritis of the knee, reports a study in the May 16, 2018 issue of The Journal of Bone & Joint Surgery.

18 May 2018

New studies could offer novel treatments for vision and eye conditions

Three new studies demonstrate research findings that could offer novel treatments for vision and eye conditions.

30 Apr 2018

Study shows limitations of AAV gene therapy in treating hereditary adrenal disorders

A new study has definitively shown that a single treatment with gene therapy using adeno-associated viral (AAV) vector gene delivery to replace the defective gene responsible for congenital adrenal hyperplasia (CAH) will only temporarily alleviate the hereditary disorder.

29 Mar 2018

Genetic variant discovery could improve safety, effectiveness of drugs for asthma and COPD

Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range of common and rare conditions including asthma, and chronic obstructive pulmonary disease (COPD).

16 Mar 2018

Novel use for drug shows promise as effective treatment for postoperative nausea and vomiting

An innovative use for a known drug is showing promise as an effective treatment for preventing postoperative nausea and vomiting, suggests a study published today in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists.

14 Mar 2018

Study shows possibility of improving pediatric asthma care

Pediatric asthma is the most common chronic childhood condition and a leading cause of pediatric hospital admissions.

2 Mar 2018

New drug candidates may offer breakthrough in treatment of COPD

The study was a cooperative effort between the team headed by assistant professor Dr Jürgen Knobloch from the Medical Clinic III for Pneumology, Sleep and Respiratory Medicine at the Bergmannsheil University Hospital in Bochum, Germany, and Prof Dr Andrea Koch, member of the German Center for Lung Research, previously in Bochum, now at the Medical Clinic V for Pneumology at the LMU University Hospital in Munich, as well as a team from the company RespiVert Ltd, a subsidiary of Janssen Biotech Inc., and Prof Dr Erich Stoelben from the Lung Clinic in Köln-Merheim.

12 Jan 2018

Untreated and overweight children may have worse asthma symptoms

Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.

19 Dec 2017

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

14 Nov 2017